NEW QUESTION 42
Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?

NEW QUESTION 43
During the review of a design dossier, the reviewer asks why the company has only carried out a top-down risk approach. The reviewer is referring to which of the following?

NEW QUESTION 44
Which of the following is the MOST desirable timing and approach for a regulatory affairs professional who wants to provide feedback on proposed new regulations?

NEW QUESTION 45
Which of the following statements regarding export regulations for an approved product is CORRECT?

NEW QUESTION 46
Which of the following double-blind clinical trial designs would be MOST appropriate for a
Phase III study with a new product intended to treat an acute life-threatening disease with less than optimal available therapy?

NEW QUESTION 47
Which of the following statements regarding the off-label use of drugs is CORRECT?

NEW QUESTION 48
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?

NEW QUESTION 49
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on the part of the PI. What action should the sponsor take?

NEW QUESTION 50
After submission to the regulatory authority, a substantial error was found in the application. In order to resolve this issue, what should be done FIRST?

NEW QUESTION 51
Which of the following BEST describes the process of post-marketing surveillance for healthcare products?

NEW QUESTION 52
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?

NEW QUESTION 53
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?

NEW QUESTION 54
A company is developing a line of products for which no ISO standard of performance is available. As a result, the company wishes to propose developing such a standard. Whom should the company contact in order to start the development of the new standard?

NEW QUESTION 55
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?

NEW QUESTION 56
According to ICH, how many stability time points are normally required to establish a two- year shelf life for a product?

NEW QUESTION 57
Why is it necessary to run supplemental safety pharmacology studies?

NEW QUESTION 58
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?

NEW QUESTION 59
What are the MOST important elements that global regulatory agencies want to know before approving a new product for sale in their countries?

NEW QUESTION 60
Which of the following BEST describes the purpose of the ICH?

NEW QUESTION 61
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?

NEW QUESTION 62
In the process of obtaining a product approval, a regulatory affairs professional discovers that the product does not meet one of the specific technical requirements of the regulation.
However, competitors with substantially similar products have claimed compliance with the requirement and received approval. Which action should the regulatory affairs professional take FIRST?

NEW QUESTION 63
As part of the regulatory strategy for companies intending to manufacture a psychotropic product, which of the following approvals should be received FIRST?